Peptidase inhibitors

A compound of Formula I:

• wherein:
• X is NR3;
• n is 1 or 2;
• A is adamantyl;
• R1 is
• wherein:
• p and q are independently 0 or 1, wherein p+q=1;
• Y is CH2, CHF, CF2, O, or S(O)m;
• W and Z are independently CH2, CHF, or CF2;
• and wherein the ring formed by N, W, Y, Z and the carbon atoms to which they are attached is saturated or optionally contains one double bond;
• R2 is R4—SO2—;
• R5—SO2—NH—C(O)—;
• or R6R7N—SO2—;
• R3 is selected from the group consisting of H, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclo, and heterocycloalkyl;
• R4 is selected from the group consisting of:
• haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclo, and heterocycloalkyl;
• R5 is selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclo, and heterocycloalkyl;
• R6 and R7 are each independently selected from the group consisting of:
• H, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclo, and heterocycloalkyl;
• or R6 and R7 together form C3-C7 alkylene;
• R8 is H or cyano;
• m is 0, 1 or 2;
• or a pharmaceutically acceptable salt thereof.